Small resident students
Release time:
2022-02-21
"mom, aunt, you go home! " At that moment, my heart was mixed. The two sisters couldn't help crying when they turned around and left. They were both sad and gratified for the baby's understanding! After
went to primary school, a more severe test was waiting for his son. Due to the inconvenience of transportation, he had to choose to live in the first grade. Due to the epidemic situation, the flow of people has been reduced. Parents can go to the dormitory to make beds for their children except for nucleic acid tests on the day of school. They are not allowed to enter the school at other times. They can only see their children on Wednesday and weekends every week. Looking at my son's thin body dragging heavy luggage, I couldn't help feeling sad, feeling that I didn't have the ability to give my child more choices. At that moment, I fought back tears and walked out of the school gate in three steps.
On the first night when I got home, all I could think about was whether I would be afraid or cry when I slept alone. After all, this was the first time my son left his family and slept alone. The anxiety kept me awake at night.
Early in the morning the next day, I waited with my cell phone for fear of missing the credit card information from my son's canteen. When I saw the pop-up consumer information prompt, I was relieved to learn that my son knew he was going to buy breakfast, and I was worried about whether he had enough. Therefore, every day in the future, the children's canteen card information has become my greatest expectation and comfort. Secondly, I am worried about my son's learning situation. I wonder if my son can adapt to such a learning atmosphere from kindergarten to grade one.
Think carefully, what on earth are you worried about? Are you worried about your children or about your school?
The photos taken by the teachers in the class group of the children are serious in class, eating on time and going to bed, showing the teachers' serious responsibility and warm care for their parents and children. Seeing the child go home happily every weekend, my heart can feel that his campus life is harmonious and happy.
In the final analysis, it is the children who are worried because of love and worry.
In an instant, the first grade life of a semester is coming to an end. As a small resident student, my son did not disappoint me. From all kinds of unhabits at the beginning of school to the present orderly, from the first little red flower in the exercise book to the first certificate of merit, I was deeply moved, which is inseparable from the teacher's hard teaching.
The growth and progress of children have taught me to let go. As the saying goes, "Parents who let go can raise promising children " . It is the best gift for parents to give their children to survive independently and adapt to society. (Chen Xiaoyan)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page